ASCO 2024: Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Posted: 07/03/2024 | By: Melissa E. Fryman, MS

The EAZ171 trial aimed to prospectively validate germline predictors of taxane-induced peripheral neuropathy and compare rates of neuropathy and dose reductions in Black women receiving paclitaxel or docetaxel for early-stage breast cancer. Results were presented by Schneider et al at the 2024 ASCO Annual Meeting and were published simultaneously in the Journal of Clinical Oncology.

Question 1 of 5

Black women with early-stage breast cancer experience higher rates of taxane-induced peripheral neuropathy compared with White women, which leads to:

Choose 1